Novo Nordisk's CagriSema Data Land Alongside a FREHEMGO Approval, a Raised Outlook and Fresh FDA Warnings
Published on 11/14/2026 at 20:40 | Editorial boerse-global.de
Novo Nordisk closed the week with a 2.7% gain, a move media reports attributed to Thursday's European approval of FREHEMGO. Yet the more consequential news for investors sits beneath the share price: a fresh readout on CagriSema, an upgraded full-year outlook, and new safety labelling requirements for its GLP-1 franchise.
CagriSema's Lower Doses Deliver Roughly 21% Weight Loss
The company released new Phase 3 results from the REDEFINE 9 study on Friday. At the lower doses, estimated average weight loss reached 20.7% and 21.0% respectively, assuming participants stayed on treatment. The figures cover a 68-week treatment period; placebo produced an estimated average reduction of 2.0%.
Novo cautioned that the trial was not designed to compare the active doses head-to-head, so the differing results do not amount to a study-validated comparison between the CagriSema doses tested. Additional visibility is due at ObesityWeek 2026 in Washington, running 14–17 November, where the company plans to present data across 26 scientific abstracts, including work on CagriSema and Wegovy.
The Bar Has Moved: ?2% to +2%
When Novo reported quarterly figures on 4 November, it lifted its 2026 guidance. Adjusted revenue growth and adjusted operating profit growth are now both expected at constant currencies in a range of ?2% to +2%, improved from the previous ?6% to 0%. That upgraded band still stretches from a decline to modest growth, which makes the direction within it the metric that matters: a result near the top would support the case that operations are regaining momentum, while a landing near the bottom would show how little headroom the raise actually bought.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Third-quarter 2026 revenue rose 4% at constant currencies, and adjusted operating profit climbed 27% on the same basis to DKK 31.7 billion. The reported picture diverges sharply. Operating profit fell 9% at constant currencies, a decline that included non-cash impairment charges of DKK 8.7 billion. Both halves of the ledger therefore deserve weight — the improvement in the adjusted business and the drag on reported earnings. The bullish reading gains credibility only if operating strength persists and starts flowing through to the bottom line as reported.
FREHEMGO Clears EU Hurdles
Thursday's approval allows FREHEMGO for routine prophylaxis in adults and children with haemophilia A, covering patients with and without inhibitors. Novo plans its first European launches next year. Patients will be able to choose monthly, fortnightly or weekly dosing, a flexibility built into the approved treatment profile. A licence opens the door to commercialisation; execution determines the economic contribution, which is why the earnings trajectory should carry more weight than the immediate market reaction.
Wegovy added its own data point on 8 November, when Novo reported a post-hoc analysis of the Phase III ESSENCE study. In adults with MASH, liver scarring and a BMI below 27 kg/m², treatment was associated with improvements across several disease markers — liver injury, fibrosis and disease activity. The findings round out the drug's medical profile, though a post-hoc analysis remains supplementary and carries correspondingly limited evidentiary weight.
FDA Adds NAION Warnings as a 2027 Catalyst Looms
Regulatory risk has moved in the opposite direction. On Monday the US Food and Drug Administration required manufacturers of GLP-1 receptor agonists to add warnings over the potentially elevated risk of NAION, a rare eye condition that can cause permanent vision loss. At Novo the requirement touches Ozempic and Wegovy. The agency cited 6.4 cases per 100,000 person-years among GLP-1 users against 3.8 cases in the comparator group.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
That labelling change feeds directly into the risk assessment of the affected medicines; any safety concern that curbs their use would tilt the balance toward the bear case, and a business trajectory drifting toward the lower end of the annual range would add further pressure.
A concrete regulatory catalyst is expected in 2027, when Novo anticipates FDA and EMA decisions on Etavopivat for sickle cell disease. The applications filed on Thursday rest on the Phase III HIBISCUS programme. Until then, the onus stays on execution: durable profits and the planned European rollout of FREHEMGO.
Ad
Novo Nordisk Stock: New Analysis - 14 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
